AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2022
Nov 19, 2022
30604_dirs_2022-11-18_41dbaa4d-9042-4e9d-967e-98ca5bf4b5d5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2022-11-16
Reporting Person: SCHELLER RICHARD H (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-16 | Common Stock | M | 3196 | — | Acquired | 53036 | Direct |
| 2022-11-16 | Common Stock | F | 1106 | $9.64 | Disposed | 51930 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-11-16 | Restricted Stock Units | $ | M | 3196 | Disposed | Common Stock (3196) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,196 shares of Common Stock underlying the Reporting Person's RSUs.
F3: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.